Champions Oncology, Inc. CSBR

Company Overview

Champions Oncology, Inc. is a U.S.-based precision oncology company focused on developing advanced research services and data solutions for the pharmaceutical and biotechnology industries. The company operates primarily in the oncology research and drug development sectors, providing translational oncology platforms designed to improve the discovery and development of cancer therapeutics. Its core offerings include patient-derived xenograft (PDX) models, ex vivo screening platforms, biomarker and genomic analysis services, and integrated preclinical oncology research solutions used by biopharma companies to evaluate drug efficacy and support clinical development programs.

The company’s principal revenue drivers are its translational oncology services and research platforms used by biotechnology and pharmaceutical customers conducting oncology-focused drug discovery and development. Champions Oncology evolved from an earlier personalized oncology model into a broader oncology research services organization serving commercial drug developers. Its strategic positioning is supported by its large proprietary tumor model database, specialized oncology expertise, and integrated research capabilities that combine biological modeling, bioinformatics, and data analytics. Public disclosures and industry reporting consistently identify oncology-focused CRO services and translational research as the company’s primary operational focus.